6.950GBp+1.31%Mkt Cap: 73.19M GBpP/E: —Last update: 2026-05-13
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Fera…
Industry Peers
Drug Manufacturers - Specialty & Generic153.14BSEKP/E 167.7
58.14BTRYP/E 27.8
51.02BEURP/E 20.1
13.68BEURP/E 31.2
13.35BTRY—
13.10BSEKP/E 39.5
3.09BTRY—
3.02BEURP/E 25.0
loading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)7.01
PEG—
P/B-6.43
P/S1.46
EV/EBITDA-7.58
EV/Revenue1.36
EPS (TTM)-0.01
EPS (Forward)0.01
Cash Flow & Leverage
FCF Yield8.53%
FCF Margin12.55%
Operating CF-3.38M GBp
CapEx (TTM)300.00K GBp
Net Debt/EBITDA-2.07
Net Debt18.51M GBp
Technical
SMA 508.285 (-16.1%)
SMA 2008.663 (-19.8%)
Beta1.88
S&P 52W Chg24.23%
Avg Vol (30d)3.05M
Avg Vol (10d)3.43M
Technical Indicators
RSI (14)28.4
MACD-0.5221
MACD Signal-0.2749
MACD Hist.-0.2471
BB Upper10.60 GBp
BB Middle8.511 GBp
BB Lower6.418 GBp
BB Width49.18%
ATR (14)0.5883 GBp
Vol Ratio (20d)0.41x
52W Range
2.20046% of range12.50
52W High12.50 GBp
52W Low2.200 GBp
Profitability
Gross Margin46.36%
EBITDA Margin-17.98%
Profit Margin-35.52%
Oper. Margin-15.07%
ROE117.10%
ROA-27.07%
Revenue Growth40.90%
Earnings Growth—
Balance Sheet
Debt/Equity-2.00
Current Ratio0.90
Quick Ratio0.72
Book Value/Sh-0.0106 GBp
Cash/Share0.0160 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.1.07B
Float278.83M
Insiders71.28%
Institutions3.20%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)17.33 GBp
Target Range14.00 GBp – 23.00 GBp
# Analysts3
Company
Market Cap73.19M GBp
Enterprise Value67.73M GBp
Revenue (TTM)49.70M GBp
Gross Profit23.04M GBp
Net Income (TTM)-17.66M GBp
Revenue/Share0.0560 GBp
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price6.950 GBp
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—